Oncology

Bladder cancer
#Bladder cancer #Drug repurposing #Mouse models #Oncology #Preclinical investigations

Diabetes and cancer drug combo shrinks bladder tumours by 91%

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) in New York has identified a promising drug combination for the treatment of muscle-invasive bladder cancer. Rosiglitazone plus trametinib worked synergistically to not only induce tumour cell death, but also shift… Read More

#Cancer Research #Editor's Choice #News

#Cystic fibrosis #Financing #Funding #Neuroscience #Oncology #Rare disease

This week in drug discovery (30 Sept – 4 Oct) 

News round-up for 30 Sept – 4 Oct by DDW Senior Digital Content Editor Diana Spencer. The theme of the news highlights this week is funding, with companies raising considerable levels of private investment, alongside new funding grants to advance the development of therapeutics for lung infections in… Read More

#News

Natural killer cells
#Cell therapy #Funding #Natural killer cells #NK:IO #Oncology

NK:IO progresses ovarian cancer natural killer therapy

Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million. The round included additional funding from UK Innovation Science and Seed Fund (UKI2S), managed by Future Planet Capital, Cambridge Angels and Cancer Research Horizons. The company says the funds will be used to… Read More

#Business & Investment #Cancer Research #News

CAR T-cells attacking a cancer cell
#CAR-T #Haematology #Myeloma #Oncology #Phase I trial #Poseida Therapeutics #Roche

Patients show 91% response to allogeneic CAR-T therapy

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More

#Cancer Research #News

#Brain cancer #Cancer Research UK #Funding #Oncology #Paediatrics

£3m boost to paediatric brain cancer research

Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours. The funding announcement comes during Childhood Cancer Awareness Month. Read More

#Cancer Research #News

#Antibody-based therapeutics #Immunotherapy #Monoclonal antibodies #Oncology

New DDW Highlights episode: 30 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The publication of DDW’s latest eBook on immunotherapy has coincided… Read More

#News

Merge road sign
#AcroImmune #Immunotherapy #Mergers and acquisitions #OncoC4 #Oncology

Immunotherapy companies OncoC4 and AcroImmune to merge

Biopharmaceutical companies OncoC4 and AcroImmune, both co-founded by CEO, Yang Liu and CMO, Pan Zheng, have entered into a definitive merger agreement. Under the terms of the agreement, OncoC4 will acquire 100% of the outstanding equity interests of AcroImmune. The merger expands OncoC4’s wholly owned immunotherapy pipeline with the addition… Read More

#Business & Investment #News

#Antibody-based therapeutics #Immunotherapy #Monoclonal antibodies #Oncology

This week in drug discovery (23-27 September) 

News round-up for 23-27 September by DDW Senior Digital Content Editor Diana Spencer. The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals. The top stories: Innovent… Read More

#News

FDA headquarters
#FDA #Monoclonal antibodies #Myeloma #Oncology #Sanofi

FDA approves Sarclisa combination for multiple myeloma

The US Food and Drug Administration (FDA) has approved Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa) for newly diagnosed multiple myeloma. It is approved in combination with bortezomib, lenalidomide, and dexamethasone for adults with who are not eligible for autologous stem cell transplant (ASCT). The efficacy of the treatment was evaluated… Read More

#News #Regulatory

Immunotherapy
#Cancer immunotherapy #eBook #Immunotherapy #Oncology

Where are the opportunities and advances in immunotherapy?

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. These treatments leverage the body’s immune system to fight disease, spanning a range of different approaches, including immune checkpoint inhibitors, adoptive cell therapies, monoclonal antibodies, oncolytic virus therapy, cancer vaccines,… Read More

#News

Lung cancer
#Immunotherapy #Lung cancer #Oncology #Preclinical investigations #The Francis Crick Institute

Triple combination treatment shrinks lung cancer tumours in mice

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have shown that a combination of treatments in mice with lung cancer allow immunotherapies to target non-responsive tumours. Their findings show that targeting tumours in different ways simultaneously might increase response to treatments. Read More

#Editor's Choice #News

Microbiome
#Drug development #Drug discovery #Mental health #Microbiome #Oncology

Hot off the press: Read the Fall issue of DDW now

The DDW Fall issue is out now and asks if the gut microbiome can unlock new therapeutics for mental health disorders, places a spotlight on oncology and includes a market report on the North American drug discovery hotspots. It also features an exclusive guide on… Read More

#Editor's Choice #News

Monoclonal antibody
#ESMO #Innovent #Monoclonal antibodies #Oncology #Solid tumours

Innovent updates ESMO 2024 on mAbs in solid tumours

Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More

#News #Trending News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights vodcast: 24 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week we have seen… Read More

#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights podcast: 23 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly… Read More

#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (16-20 September) 

News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. The top stories: Study shows low… Read More

#News